CYTOMED THERAPEUTICS LTD (GDTC) Stock Price, Quote, News and Overview
NASDAQ:GDTC - Nasdaq - SGXZ17669631 - Common Stock - Currency: USD
GDTC Quote, Performance and Key Statistics
1.77
-0.03 (-1.67%)
The current stock price of GDTC is 1.77 USD. In the past month the price decreased by -13.24%. In the past year, price increased by 6.46%.
GDTC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.76 | 350.88B | ||
| AMGN | AMGEN INC | 13.07 | 153.24B | ||
| GILD | GILEAD SCIENCES INC | 15.51 | 149.30B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.89 | 99.58B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.19 | 60.09B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 56.06B | ||
| ARGX | ARGENX SE - ADR | 68.78 | 39.02B | ||
| ONC | BEONE MEDICINES LTD-ADR | 4.5 | 31.18B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.68B | ||
| INSM | INSMED INC | N/A | 23.14B | ||
| NTRA | NATERA INC | N/A | 21.82B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.08B |
Related stock screener links
About GDTC
Company Profile
CytoMed Therapeutics Ltd. is a biopharmaceutical company, which engages in the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy, and undertaking the research and development of immune cell and stem cell-based therapy. The company employs 34 full-time employees The company went IPO on 2023-04-14. The company is focused on harnessing its licensed proprietary technologies, namely gamma delta T cell and gamma delta Natural Killer T cel to create cell-based immunotherapies for the treatment of human cancers. The development of its technologies has been inspired by the clinical success of existing CAR-T in treating hematological malignancies as well as the clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors. Its product candidates include CTM-N2D, iPSC-gdNKT, and CTM-GDT. CTM-N2D is a lead product candidate that consists of expanded gamma delta T cells grafted with NKG2DL-targeting CAR to enhance anti-cancer cytotoxicity. The iPSC-gdNKT product candidate utilizes iPSC as a starting material to generate gdNKT, which is a synthetic hybrid of a gamma delta T cell and a NK cell. The CTM-GDT product candidate consists of expanded allogeneic gamma delta T cells.
Company Info
CYTOMED THERAPEUTICS LTD
#08-22 One Commonwealth, 1 Commonwealth Lane
Singapore SG
Employees: 34
Phone: 65603824911
CYTOMED THERAPEUTICS LTD / GDTC FAQ
What is the stock price of CYTOMED THERAPEUTICS LTD today?
The current stock price of GDTC is 1.77 USD. The price decreased by -1.67% in the last trading session.
What is the ticker symbol for CYTOMED THERAPEUTICS LTD stock?
The exchange symbol of CYTOMED THERAPEUTICS LTD is GDTC and it is listed on the Nasdaq exchange.
On which exchange is GDTC stock listed?
GDTC stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CYTOMED THERAPEUTICS LTD stock?
7 analysts have analysed GDTC and the average price target is 5.1 USD. This implies a price increase of 188.14% is expected in the next year compared to the current price of 1.77. Check the CYTOMED THERAPEUTICS LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CYTOMED THERAPEUTICS LTD worth?
CYTOMED THERAPEUTICS LTD (GDTC) has a market capitalization of 20.43M USD. This makes GDTC a Nano Cap stock.
How many employees does CYTOMED THERAPEUTICS LTD have?
CYTOMED THERAPEUTICS LTD (GDTC) currently has 34 employees.
What are the support and resistance levels for CYTOMED THERAPEUTICS LTD (GDTC) stock?
CYTOMED THERAPEUTICS LTD (GDTC) has a resistance level at 1.88. Check the full technical report for a detailed analysis of GDTC support and resistance levels.
Is CYTOMED THERAPEUTICS LTD (GDTC) expected to grow?
The Revenue of CYTOMED THERAPEUTICS LTD (GDTC) is expected to grow by 31.87% in the next year. Check the estimates tab for more information on the GDTC EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CYTOMED THERAPEUTICS LTD (GDTC) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GDTC, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GDTC, evaluating the profitability, health, valuation and growth aspects
- CYTOMED THERAPEUTICS LTD (GDTC) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CYTOMED THERAPEUTICS LTD (GDTC) Sales and EPS estimates to see what analysts future expectations are.
- CYTOMED THERAPEUTICS LTD (GDTC) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CYTOMED THERAPEUTICS LTD (GDTC) Insider and Institutional Ownership to learn about the owners and their transactions.
- CYTOMED THERAPEUTICS LTD (GDTC) Stock Chart to make your own analysis
- CYTOMED THERAPEUTICS LTD (GDTC) Latest news and press-releases to stay up to date.
Does CYTOMED THERAPEUTICS LTD (GDTC) stock pay dividends?
GDTC does not pay a dividend.
When does CYTOMED THERAPEUTICS LTD (GDTC) report earnings?
CYTOMED THERAPEUTICS LTD (GDTC) will report earnings on 2025-09-30.
What is the Price/Earnings (PE) ratio of CYTOMED THERAPEUTICS LTD (GDTC)?
CYTOMED THERAPEUTICS LTD (GDTC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.2).
What is the Short Interest ratio of CYTOMED THERAPEUTICS LTD (GDTC) stock?
The outstanding short interest for CYTOMED THERAPEUTICS LTD (GDTC) is 1.49% of its float. Check the ownership tab for more information on the GDTC short interest.
GDTC Technical Analysis
GDTC Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to GDTC. GDTC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
GDTC Financial Highlights
Over the last trailing twelve months GDTC reported a non-GAAP Earnings per Share(EPS) of -0.2. The EPS increased by 60.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.82% | ||
| ROE | -30.6% | ||
| Debt/Equity | 0.04 |
GDTC Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to GDTC. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 42.31% and a revenue growth 31.87% for GDTC